CLDN4 and breast carcinoma: Single agent treatment with a human monoclonal anti-CLDN4 antibody (4D3, Table 1), resulted in moderate effects on in vitro cell growth inhibition across bladder, CRC, gastric, pancreatic or breast cancer cells (48–51, 68).